NCT03970447 2026-04-22
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
Clinical Trials
15 trialsNCT06325683 2026-04-21
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
NCT06336291 2026-04-21
GLIOSTELLA
Philogen S.p.A.
Phase 2 Active not recruiting
NCT07100730 2026-04-16
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT04762069 2026-04-15
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
CNS Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT06419946 2026-04-13
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Vastra Gotaland Region
Phase 3 Recruiting
NCT05095376 2026-04-03
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
Phase 3 Active not recruiting
NCT05904119 2026-02-17
LEGATO
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT04049669 2026-01-08
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Augusta University
Phase 2 Active not recruiting
NCT01582269 2025-11-24
A Study in Recurrent Glioblastoma (GB)
Eli Lilly and Company
Phase 2 Completed
NCT05902169 2025-11-10
SONOBIRD
CarThera
Phase 3 Active not recruiting
NCT07145112 2025-10-09
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
University of California, Davis
Phase 1 Recruiting
NCT04863950 2025-08-27
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT06177964 2025-08-17
Lerapolturev (PVSRIPO) in GBM
Duke University
Phase 2 Recruiting
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed